23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Financial News

PharmAbcine completes venture financing

PharmAbcine Inc. , Daejon, South Korea   Business: Antibodies   Date completed: 9/16/09   Type: Venture financing   Raised: $6 million   Investors: Caduceus Capital; Novartis Korea Venture Fund; Green Cross; Tong Yang Venture Capital...
08:00 , Dec 22, 2003 |  BioCentury  |  Finance

Ebb & Flow

Last week's financing activity illustrated the variety of paths companies are taking in this uncertain IPO market. Two companies that had pulled earlier attempts at IPOs took distinctively different paths, with Idenix tossing its hat...
08:00 , Dec 17, 2003 |  BC Extra  |  Financial News

Peninsula files for IPO

Peninsula Pharmaceuticals filed to raise up to $86.3 million in an IPO underwritten by CS First Boston; U.S. Bancorp Piper Jaffray; Citigroup; and First Albany. The company in-licenses compounds to treat infectious diseases. Its lead...
07:00 , Apr 15, 2002 |  BioCentury  |  Finance

Ebb & Flow

What happened to all of the window-wishers; those who would run around even in the worst of bear markets predicting that a robust IPO window is just around the corner? Even with a slate of...
07:00 , Jul 28, 2000 |  BC Extra  |  Financial News

Enanta raises $20 million

Enanta ( Cambridge , Mass.) raised $20 million in a private financing through Oxford Bioscience Partners; Advent International; TVM Techno Venture Management; Caduceus Capital; Bank Vontobel; Alpinvest International; and KB Lux Venture Capital. Enanta uses...
08:00 , Jan 25, 1999 |  BioCentury  |  Finance

Genentech pushes past a magic number

While Genentech posted solid 1998 earnings last week, investors will have only one more look at a GNE P&L statement prior to Roche 's June 30 deadline to exercise its option to buy the 34.7...